Investing Center Preview – Manage your investments and watch your net worth grow.
ABBV:NYSE – Large Cap Stock (Drug Manufacturers)
AbbVie Inc – ABBV Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
185.48 | -5.38 (-2.82%) | 163.52 - 218.66 | 4.7 million |
Market data as of 4:00PM 06/17/25. Quotes are delayed by at least 15 min.
Overview - ABBV
Open | 189.16 |
---|---|
Previous Close | 190.86 |
Day's Range | 185.03 - 190.61 |
Market Cap | 327.6B |
Avg Volume (10 Day) | 4.5M |
Price/Earnings (Trailing 12 Mo.) | 81.7x |
Earnings Per Share (Trailing 12 Mo.) | 1.819 |
Dividend Yield | 1.64 (3.54%) |
One-Click Scorecard - ABBV


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Fail |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - ABBV
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
PR Newswire - Monday 06/16/2025 9:00 AM ET
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
PR Newswire - Wednesday 06/11/2025 12:31 PM ET
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
PR Newswire - Tuesday 06/03/2025 8:15 AM ET
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
PR Newswire - Tuesday 06/03/2025 8:00 AM ET
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
PR Newswire - Friday 05/30/2025 8:00 AM ET
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
PR Newswire - Tuesday 05/27/2025 9:00 AM ET
Industry Position - ABBV
ABBV | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 3.71% | |
Net Income Growth (1yr) | -12.03% | |
Total Debt/Equity | 49.22 | |
LT Debt/Equity | 45.44 | |
Earnings Yield | 1.22% | |
Price/Sales | 5.90 |
Competitors - ABBV
Company | Last | Change |
---|---|---|
51.84 | -3.57% | |
Johnson & Johnson | 152.38 | -1.83% |
5885.00 | +0.11% | |
261.60 | -0.49% | |
Merck & Co Inc | 78.28 | -3.31% |
Data is delayed by at least 15 min.